Jason O’Byrne, MBA, serves as Executive Vice President and Chief Financial Officer (CFO). Mr. O’Byrne leads the Finance, Investor Relations, Operations and IT organizations at Vir Biotechnology. He has spent over 20 years in finance and operations with demonstrated effective financial leadership in capital allocation and formation, corporate strategy and operational execution.
Prior to joining Vir Biotechnology in October 2024, Mr. O’Byrne served as CFO at Caribou Biosciences, where he managed the Finance, Investor Relations, Corporate Communications, IT and the Operations organizations. He also led multiple capital formation initiatives at Caribou, including the IPO in 2021 and a follow-on offering in 2023. Previously, Mr. O’Byrne served as Senior Vice President of Finance at Audentes Therapeutics, where he oversaw the financial due diligence and integration related to the company’s $3 billion acquisition by Astellas Pharma in 2020. Earlier in his career, Mr. O’Byrne spent 13 years with Genentech and its parent company Roche, holding finance leadership and executive positions of increasing responsibility and geographical reach and building broad operational finance expertise across manufacturing, research, clinical development, business development and commercial functions. During his Genentech/Roche tenure, he served as Vice President, Head of Finance for Roche Asia-Pacific and Vice President, Global Head of Finance for Product Development and Product Strategy.
Mr. O’Byrne holds an MBA in Finance, with distinction, from New York University’s Stern School of Business and a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia.
What is Jason O'Byrne's net worth?
The estimated net worth of Jason O'Byrne is at least $1.47 million as of February 24th, 2026. Mr. O'Byrne owns 162,615 shares of Vir Biotechnology stock worth more than $1,473,292 as of April 5th. This net worth approximation does not reflect any other investments that Mr. O'Byrne may own. Learn More about Jason O'Byrne's net worth.
How do I contact Jason O'Byrne?
Has Jason O'Byrne been buying or selling shares of Vir Biotechnology?
Jason O'Byrne has not been actively trading shares of Vir Biotechnology during the last quarter. Most recently, Jason O'byrne sold 1,634 shares of the business's stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $9.53, for a transaction totalling $15,572.02. Following the completion of the sale, the chief financial officer now directly owns 162,615 shares of the company's stock, valued at $1,549,720.95. Learn More on Jason O'Byrne's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Marianne De Backer (CEO & Director), Vanina de Verneuil (EVP, General Counsel and Corporate Secretary), Mark Eisner (Executive Vice President and Chief Medical Officer), Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Jason O'Byrne (Executive Vice President and Chief Financial Officer), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Brent Sabatini (CAO), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 52 times. They sold a total of 3,318,505 shares worth more than $20,488,792.06. The most recent insider tranaction occured on April, 1st when Director Vicki L Sato sold 22,000 shares worth more than $199,540.00. Insiders at Vir Biotechnology own 16.0% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 4/1/2026.
